Issue 52

Will the UK be the first European country to embrace psilocybin-assisted therapy?

At Prime Minister’s Questions, Boris Johnson responded to Tory MP Crispin Blunt’s call to reschedule psilocybin. Johnson told the house that he would consider ‘recent advice on reducing barriers to research with controlled drugs’, in a statement that galvanised the country’s biosciences industry.

Advocates hope the UK could soon move psilocybin, and other compounds, to Schedule 2 to reflect mounting evidence on their therapeutic potential. This would facilitate greater medical research, laying the foundations for a domestic market with direct access to London’s capital markets.

COMPASS PATHWAYS SHARES DATA FROM COMP360 OPEN-LABEL STUDY

Fifty per cent of participants achieved remission in depression symptoms, sustained for the eight-week follow-up period.

WHERE THE PSYCHEDELIC REVOLUTION IS HEADED

Rick Doblin, Founder of MAPS, spoke with GQ Magazine on the psychedelic healthcare industry’s roadmap and treating PTSD with MDMA.

BUSINESS AND INVESTMENT

Beckley Psytech doses first patient in clinical trials with 5-MeO-DMT.

The new world of psychedelics.

Numinus finalises design and protocol for Phase I clinical trial with psilocybin.

Ketamine One partners with Biostrap on wearable devices for clinical trials.

Small Pharma receives Innovation Passport Designation for DMT study.

Mindset Pharma shares 2021 financial results.

MINDCURE reports Q1 2022 financial results.

FDA puts Tryp Therapeutics’ clinical trial on hold.

Mind Med launches MDMA programme to treat social anxiety.

Patent highlights the swirling battle over psychedelics’ intellectual property.

Cybin receives FDA approval for ketamine study.

The Psychedelics as Medicine Report: Third Edition

The 200+ page Psychedelics as Medicine Report: Third Edition is the most comprehensive analysis of the psychedelic healthcare industry, empowering investors, operators and regulators to make informed decisions.

Key findings:

The medical psychedelic market is valued at US$190 million, and is expected to exceed US$2.4 billion by 2026.
Investment in psychedelic companies has now surpassed US$2 billion.
Two-thirds of North Americans and Europeans support the legalisation of psychedelic-assisted therapy.

Download your complimentary copy

SCIENCE AND RESEARCH

University College London launches tryptamine research project.

University Health Network receives C$5m donation.

Recent progress in psychedelic therapies.

Ketamine and psilocybin showing promise for treatment of mood disorders.

Study protocol for ‘Psilocybin as a Treatment for Anorexia Nervosa’.

Magic mushrooms can help smokers butt out.

Telegraph: ‘LSD is the purest, cleanest drug of all.’

How ketamine therapy helped this Canadian veteran.

Countdown to ecstasy: how music is being used in healing psychedelic trips.

Mind Medicine Australia, 17–20 November

10% DISCOUNT CODE: MMA2021

REGULATION AND LEGISLATION

Easthampton City Council votes to decriminalise entheogens.

Dr. Bronner’s funds psilocybin legalisation campaign in Connecticut.

Activists in Washington D.C launch campaign to decriminalise psychedelics.